016790 — CanariaBio Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesHighly SpeculativeSmall Cap

Annual income statement for CanariaBio, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	118,173	107,477	110,306	158,096	160,601
Cost of Revenue
Gross Profit	18,122	17,034	12,133	19,107	22,689
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	112,335	107,911	109,687	443,030	316,940
Operating Profit	5,838	-434	619	-284,935	-156,340
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	4,173	275	-920	-281,872	-208,712
Provision for Income Taxes
Net Income After Taxes	3,245	128	-725	-282,751	-208,328
Net Income Before Extraordinary Items
Net Income	3,245	128	-725	-282,751	-208,328
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	3,245	128	-725	-282,751	-208,328
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	10.3	9.98	-2.42	-892	-713
Dividends per Share